Neoadjuvante Therapie des Kolonkarzinoms

Die neoadjuvante Therapie ist bei der Behandlung von Kolonkarzinomen bislang noch kein etablierter Standard. Die Entwicklung derselben kommt in letzter Zeit jedoch voran – derzeit werden ganz verschiedene Konzepte verfolgt. Dieser Artikel stellt die aktuelle Datenlage dar und gibt zudem einen Ausblick auf die möglichen weiteren Entwicklungen der neoadjuvanten Therapie.

Schlüsselwörter

Kolonkarzinom - neoadjuvante Therapie - Chemotherapie - MSI-H/dMMR

Publication History

Article published online:
04 August 2025

• Literatur

• 1 Argiles G, Tabernero J, Labianca R. et al. Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2020; 31 (10) 1291-1305
• 2 Tie J, Cohen JD, Lahouel K. et al. Circulating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II Colon Cancer. N Engl J Med 2022; 386 (24) 2261-2272
• 3 Tie J, Wang Y, Cohen J. et al. Circulating tumor DNA dynamics and recurrence risk in patients undergoing curative intent resection of colorectal cancer liver metastases: A prospective cohort study. PLoS Med 2021; 18 (05) e1003620
• 4 Kataoka K, Mori K, Nakamura Y. et al. Survival benefit of adjuvant chemotherapy based on molecular residual disease detection in resected colorectal liver metastases: subgroup analysis from CIRCULATE-Japan GALAXY. Ann Oncol 2024; 35 (11) 1015-1025
• 5 Kotani D, Oki E, Nakamura Y. et al. Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer. Nat Med 2023; 29 (01) 127-134
• 6 Morton D, Seymour M, Magill L. et al. Preoperative Chemotherapy for Operable Colon Cancer: Mature Results of an International Randomized Controlled Trial. J Clin Oncol 2023; 41 (08) 1541-1552
• 7 Cercek A, Lumish M, Sinopoli J. et al. PD-1 Blockade in Mismatch Repair-Deficient, Locally Advanced Rectal Cancer. N Engl J Med 2022; 386 (25) 2363-2376
• 8 Verheij FS, Omer DM, Williams H. et al. Long-Term Results of Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy: The Randomized Phase II OPRA Trial. J Clin Oncol 2024; 42 (05) 500-506
• 9 Al-Batran SE, Homann N, Pauligk C. et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet 2019; 393: 1948-1957
• 10 Cunningham D, Allum WH, Stenning SP. et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006; 355 (01) 11-20
• 11 Conroy T, Bosset JF, Etienne PL. et al. Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 2021; 22 (05) 702-715
• 12 Glynne-Jones R, Wyrwicz L, Tiret E. et al. Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2017; 28 (Suppl. 04) iv22-iv40
• 13 Bahadoer RR, Dijkstra EA, van Etten B. et al. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial. Lancet Oncol 2021; 22 (01) 29-42
• 14 Shkurti J, van den Berg K, van Erning FN. et al. Diagnostic accuracy of CT for local staging of colon cancer: A nationwide study in the Netherlands. Eur J Cancer 2023; 193: 113314
• 15 Chalabi M, Fanchi LF, Dijkstra KK. et al. Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers. Nat Med 2020; 26 (04) 566-576
• 16 Chalabi M, Verschoor YL, Tan PB. et al. Neoadjuvant Immunotherapy in Locally Advanced Mismatch Repair-Deficient Colon Cancer. N Engl J Med 2024; 390 (21) 1949-1958
• 17 de Gooyer PGM, Verschoor YL, van den Dungen LDW. et al. Neoadjuvant nivolumab and relatlimab in locally advanced MMR-deficient colon cancer: a phase 2 trial. Nat Med 2024; 30 (11) 3284-3290
• 18 Hu H, Zhang J, Li Y. et al. Neoadjuvant Chemotherapy With Oxaliplatin and Fluoropyrimidine Versus Upfront Surgery for Locally Advanced Colon Cancer: The Randomized, Phase III OPTICAL Trial. J Clin Oncol 2024; 42 (25) 2978-2988
• 19 Jensen LH, Kjaer ML, Larsen FO. et al. Phase III randomized clinical trial comparing the efficacy of neoadjuvant chemotherapy and standard treatment in patients with locally advanced colon cancer: The NeoCol trial. Journal of Clinical Oncology 2023; 41 (Suppl. 17) LBA3503-LBA
• 20 Karoui M, Rullier A, Piessen G. et al. Perioperative FOLFOX 4 Versus FOLFOX 4 Plus Cetuximab Versus Immediate Surgery for High-Risk Stage II and III Colon Cancers: A Phase II Multicenter Randomized Controlled Trial (PRODIGE 22). Ann Surg 2020; 271 (04) 637-645
• 21 Seymour M. FOxTROT: an international randomised controlled trial in 1052 patients (pts) evaluating neoadjuvant chemotherapy (NAC) for colon cancer. J Clin Oncol 2019; 37 (suppl; abstr 3504).
• 22 Andre T, Shiu KK, Kim TW. et al. Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer. N Engl J Med 2020; 383 (23) 2207-2218
• 23 Andre T, Elez E, Van Cutsem E. et al. Nivolumab plus Ipilimumab in Microsatellite-Instability-High Metastatic Colorectal Cancer. N Engl J Med 2024; 391 (21) 2014-2026
• 24 Taieb J, Svrcek M, Cohen R. et al. Deficient mismatch repair/microsatellite unstable colorectal cancer: Diagnosis, prognosis and treatment. Eur J Cancer 2022; 175: 136-157
• 25 Sinicrope FA, Sargent DJ. Molecular pathways: microsatellite instability in colorectal cancer: prognostic, predictive, and therapeutic implications. Clin Cancer Res 2012; 18 (06) 1506-1512
• 26 Starling N, Neumann K, Colwell B. et al. AZUR-2, a phase III, open-label, randomized study of perioperative dostarlimab monotherapy vs standard of care in previously untreated patients with T4N0 or stage III dMMR/MSI-H resectable colon cancer. Journal of Clinical Oncology 2024; 42 (Suppl. 03) TPS240-TPS
• 27 Duval M, Vanderbecq Q, Phou V. et al. Performances of preoperative CT scan to predict the pTN stage for MSI/dMMR localized colon cancers. ESMO Open 2024; 9 (08) 103678